Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
Digestion · 2024
DOI: 10.1159/000541383 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Digestion, 2024. Verfasst von Ken Takeuchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Here, we report the primary analysis of a phase 3 trial evaluating the efficacy and safety of etrasimod in patients from Japan with moderately to severely active UC.
Methods
Patients from Japan who completed the 12-week ELEVATE UC 12 induction trial could enroll in the 40-week ELEVATE UC 40 JAPAN maintenance trial for a combined 52-week treatment period. Patients in this Japan cohort continued their baseline assigned treatment (etrasimod 2 mg QD or placebo) from ELEVATE UC 12. Efficacy was assessed at week 12 and week 52. Treatment-emergent adverse events (TEAEs) pooled from both trials were assessed up to 52 weeks of exposure.
Results
The Japan cohort comprised 32 and 16 patients who received etrasimod and placebo, respectively. A numerically greater proportion of patients who received etrasimod versus placebo achieved clinical remission at week 12 (etrasimod: 14.3%; placebo: 7.1%) and week 52 (etrasimod: 25.0%; placebo: 7.1%); a similar trend was observed for all key secondary efficacy endpoints. TEAEs occurred in 84.4% (27/32) and 62.5% (10/16) of patients who received etrasimod and placebo, respectively. No new safety signals were detected.
Conclusion
In these induction and maintenance trials evaluating etrasimod in patients from Japan with UC, numerically higher proportions of patients who received etrasimod versus placebo achieved efficacy endpoints. Efficacy and safety findings were consistent with those from the global ELEVATE UC trial populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
- Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
- Pfizer Inc, New York, New York, USA.
- Pfizer R&D Japan, Tokyo, Japan.
Zitieren
APA
Takeuchi, K., Hisamatsu, T., Nakase, H., Matsuoka, K., Keating, M., Yuasa, H., Oe, M., Arai, S., Mazur, R., & Hibi, T. (2024). Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials. Digestion. https://doi.org/10.1159/000541383
Vancouver
Takeuchi K, Hisamatsu T, Nakase H, Matsuoka K, Keating M, Yuasa H, et al. Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials. Digestion. 2024. doi:10.1159/000541383
BibTeX
@article{Takeuchi2024,
author = {Takeuchi, Ken and Hisamatsu, Tadakazu and Nakase, Hiroshi and Matsuoka, Katsuyoshi and Keating, Michael and Yuasa, Hirotoshi and Oe, Motoki and Arai, Shoko and Mazur, Rafal and Hibi, Toshifumi},
title = {Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials},
journal = {Digestion},
year = {2024},
doi = {10.1159/000541383}
}
EUVIMED